Department of Gastroenterology and Hepatology, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Department of Public Health, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Gut. 2017 Jan;66(1):118-123. doi: 10.1136/gutjnl-2014-308957. Epub 2015 Sep 14.
Limited data exist on attendance and additional yield of 2-sample faecal immunochemical testing (FIT) screening during multiple rounds. We therefore conducted a population-based colorectal cancer screening trial comparing attendance and yield of repeated 1-sample and 2-sample FIT screenings.
Two randomly selected groups of average-risk subjects aged 50-74 years were invited for two rounds of either 1-sample (n=5007) or 2-sample (n=3197) FIT (OC-sensor Micro) screening. The test was considered positive if at least one sample was positive (cut-off 50 ng/mL; 10 µg haemoglobin/g).
The cumulative attendance rate was similar for repeated 1-sample and 2-sample FIT screenings (1-sample FIT: 68.1%; 2-sample FIT: 67.1%, p=0.368). The positivity rate in the second round was lower for 1-sample FIT (6.2%, 95% CI 5.4% to 7.2%) than for 2-sample FIT (8.4%, 95% CI 7.1% to 9.8%, p=0.007), whereas the detection rate of advanced neoplasia (AN, 1-sample FIT: 1.9%, 95% CI 1.2% to 2.2%; 2-sample FIT: 1.7%, 95% CI 1.2% to 2.5%, p=0.861) and the positive predictive value (1-sample FIT: 32%, 95% CI 24% to 40%; 2-sample FIT: 21%, 95% CI 15% to 29%, p=0.075) did not differ. After two rounds of screening, the cumulative diagnostic yield of AN for 1-sample FIT was 29.3 per 1000 invitees, compared with 34.0 for 2-sample FIT (p=0.241).
Using 2-sample FIT instead of 1-sample FIT does not result in a higher detection rate of AN in the second round of repeated FIT screening. Furthermore, both strategies lead to a similar yield of AN over two rounds. These findings imply that 1-sample FIT screening is preferred over 2-sample FIT screening.
关于多次轮次中进行两样本粪便免疫化学检测(FIT)筛查的出席率和额外检出率,目前仅有有限的数据。因此,我们开展了一项基于人群的结直肠癌筛查试验,比较了重复进行单样本和双样本 FIT 筛查的出席率和检出率。
随机选择两组年龄在 50-74 岁的一般风险受试者,邀请他们参加两轮单样本(n=5007)或双样本(n=3197)FIT(OC-sensor Micro)筛查。如果至少一个样本呈阳性(截止值 50ng/mL;10µg 血红蛋白/g),则认为该检测为阳性。
重复进行单样本和双样本 FIT 筛查的累积出席率相似(单样本 FIT:68.1%;双样本 FIT:67.1%,p=0.368)。第二轮单样本 FIT 的阳性率(6.2%,95%CI 5.4%至 7.2%)低于双样本 FIT(8.4%,95%CI 7.1%至 9.8%,p=0.007),而高级别肿瘤(AN,单样本 FIT:1.9%,95%CI 1.2%至 2.2%;双样本 FIT:1.7%,95%CI 1.2%至 2.5%,p=0.861)的检出率和阳性预测值(单样本 FIT:32%,95%CI 24%至 40%;双样本 FIT:21%,95%CI 15%至 29%,p=0.075)并无差异。两轮筛查后,单样本 FIT 的 AN 累积诊断率为每 1000 名受邀者 29.3 例,而双样本 FIT 为 34.0 例(p=0.241)。
与单样本 FIT 相比,使用双样本 FIT 不会导致第二轮重复 FIT 筛查中 AN 的检出率更高。此外,两种策略在两轮筛查中均导致 AN 的检出率相似。这些发现意味着单样本 FIT 筛查优于双样本 FIT 筛查。